S. Lakhanpal

Phase II Study of 4-Ipomeanol, a Naturally Occurring Alkylating Furan, in Patients with Advanced Hepatocellular Carcinoma

R. Donehower, E. Rowinsky, S. Lakhanpal, 2004, Investigational New Drugs.

A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.

C. Flowers, W. Stock, Jennifer R. Brown, 2015, Clinical lymphoma, myeloma & leukemia.

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

R. Marcus, D. Furst, K. Dao, 2019, Arthritis Care & Research.

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

D. Furst, K. Dao, M. Rosen, 2019, Arthritis care & research.

Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study

M. Karuturi, S. Lakhanpal, C. DiCristo, 2023, Breast cancer research and treatment.

Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).

C. Flowers, W. Stock, Jennifer R. Brown, 2007 .

Measures of functional status in older patients treated with palbociclib for advanced breast cancer.

M. Karuturi, G. Rocque, S. Lakhanpal, 2023, Journal of geriatric oncology.